Title: Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017 Document date: 2017_11_7
ID: roslkxeq_532
Snippet: Disclosures: Disclosures to report. This study was a population study and involved no conflict of interest by the authors. One of the authors (BD) is employed by the accredited laboratory that was the source of the raw data. One of the authors (SF) is a consultant to the same laboratory. The study was an independent collaborative retrospective study. It was not performed for any commercial benefit and was not funded by any person or entity. Hyper.....
Document: Disclosures: Disclosures to report. This study was a population study and involved no conflict of interest by the authors. One of the authors (BD) is employed by the accredited laboratory that was the source of the raw data. One of the authors (SF) is a consultant to the same laboratory. The study was an independent collaborative retrospective study. It was not performed for any commercial benefit and was not funded by any person or entity. Hyperthyroidism leads to a decrease in serum creatinine (Crea) by increasing glomerular filtration rate (GFR) and decreasing body muscle mass. This can mask a concurrent chronic kidney disease that might become evident after the onset of treatment. Symmetric dimethylarginine (SDMA) is a novel, early, renal biomarker independent of body muscle mass, therefore it might be a useful marker of renal disease in hyperthyroid cats. In humans is not clear if hyperthyroid state could influence SDMA.
Search related documents:
Co phrase search for related documents- interest conflict and retrospective study: 1, 2, 3
- kidney disease and muscle mass: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- kidney disease and population study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- kidney disease and renal biomarker: 1, 2, 3, 4, 5, 6, 7, 8
- kidney disease and renal disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- kidney disease and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- kidney disease and SDMA symmetric dimethylarginine: 1, 2, 3, 4, 5, 6, 7, 8, 9
- kidney disease and serum creatinine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- kidney disease and symmetric dimethylarginine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- kidney disease and treatment onset: 1
- kidney disease and useful marker: 1
- muscle mass and population study: 1, 2, 3
- muscle mass and renal biomarker: 1, 2
- muscle mass and retrospective study: 1, 2, 3, 4, 5, 6, 7
- muscle mass and SDMA symmetric dimethylarginine: 1, 2, 3
- muscle mass and serum creatinine: 1, 2, 3, 4, 5
- muscle mass and symmetric dimethylarginine: 1, 2, 3, 4
- population study and renal biomarker: 1
- population study and renal disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date